TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›GRFS

GRFS

Grifols SA

Next earnings Jul 27, 2026 · consensus $0.13 EPS, $1.77B rev

Sell
$7.16
▼ -2.32%
$7.16▼ -17.85%
over 1Y
L $7.16H $10.74
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-2.3%
1W-2.8%
1M-6.2%
3M-13.1%
YTD-22.5%
1Y-17.8%
OverviewValuationQualityFilings
Rating
Sell
Quality
F
Valuation
Fair value
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 21 analysts
Buy

Mixed signals in the latest filings.

Grifols SA shows limited reported revenue.

On these fundamentals, GRFS screens as SELL on the SEC figures.

Rule-based analysis, generated automatically from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 10:16 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Key statistics

Valuation

Enterprise value$4.87B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—

Quality & risk

ROIC (est.)—
Free cash flow—
Total debt—
Net cash—

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Recent filings

all on EDGAR ↗
6-KPeriod ending 2026-06-222026-06-22open ↗6-KPeriod ending 2026-06-182026-06-18open ↗6-KPeriod ending 2026-05-152026-05-15open ↗SCHEDULE 13G/AFiling2026-05-14open ↗6-KPeriod ending 2026-05-072026-05-07open ↗20-FPeriod ending 2025-12-312026-04-17open ↗6-KPeriod ending 2026-04-142026-04-14open ↗6-KPeriod ending 2026-03-242026-03-24open ↗6-KPeriod ending 2026-02-262026-02-26open ↗6-KPeriod ending 2026-02-262026-02-26open ↗SCHEDULE 13G/AFiling2026-02-17open ↗SCHEDULE 13G/AFiling2026-02-12open ↗

Quality score

F
ValueGrowthProfitHealthMom.
Value—
Growth—
Profitability—
Financial health—
MomentumF
6.9952-week10.60
Revenue
—
Net margin
—
ROE
—
P/E
—

SEC fundamentals

Frequently asked

Is Grifols SA (GRFS) a buy?
GRFS currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
What is Grifols SA's quality score?
GRFS scores 21.053790845993923/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001438569, latest 6-K filed 2026-06-22) · EODHD · as of 7/4/2026, 2:16:25 PM.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Dividends

Semi-annual
Yield (TTM)
3.7%
Annual / share
$0.27
Last ex-date
2026-07-02
Last amount
$0.09
ex 2026-07-02paid 2026-07-09$0.09
ex 2025-08-12paid 2025-08-20$0.17
ex 2021-06-03paid 2021-06-14$0.46
ex 2020-10-30paid 2020-11-09$0.20
ex 2019-12-02paid 2019-12-11$0.22
ex 2019-06-07paid 2019-06-18$0.17

Source: EODHD. Yield = trailing-12-month dividends ÷ price.

Congressional trades

all activity →

Disclosed under the STOCK Act

2023-04-17Daniel GoldmanSell$1.00K–$15.0KPTR ↗
2023-03-20Daniel GoldmanBuy$1.00K–$15.0KPTR ↗
2019-12-23Greg GianforteSell$100K–$250KPTR ↗

Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.

Recent news

market news →
Jazz Pharmaceuticals and AbCellera Biologics Inc. (ABCL) Announce CollaborationBullish
finance.yahoo.com· 2026-06-23
Grifols (GRFS) Launches FESILTY in the U.S. for Congenital Fibrinogen Deficiency TreatmentBullish
finance.yahoo.com· 2026-06-19
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.Bullish
finance.yahoo.com· 2026-06-15
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
finance.yahoo.com· 2026-06-09
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
finance.yahoo.com· 2026-06-08
Grifols, S.A. (GRFS) Sees Strong Biopharma Growth Led by Gamunex and YimmugoBullish
finance.yahoo.com· 2026-06-02

Vs tracked universe

compare →

1195 tracked peers · median

TENK Score21 vs 67
Revenue growth— vs 7.5%
Net margin— vs 10.0%
Return on equity— vs 12.0%
P/E— vs 26.2

News sentiment

EODHD · 14d
Bullish
+0.17
vs typical · 16 articles

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.